Jiangsu Hechen Pharmaceutical

Jiangsu Hechen Pharmaceutical Co., Ltd., established in 2020 and headquartered in Lianyungang, China, is a specialized biopharmaceutical company and CDMO focusing on high-end oral solid preparations. As a wholly-owned subsidiary of Zhejiang Heze Pharmaceutical Technology, the company plays a pivotal role in the group's Marketing Authorization Holder (MAH) strategy, providing comprehensive CDMO and GMP services. Hechen specializes in complex formulations, including sustained-release tablets, orodispersible films, and high-potency (OEB3+) drugs, utilizing advanced technologies such as hot-melt extrusion and spray drying. The company has successfully commercialized several products in China, including treatments for Parkinson's disease, schizophrenia, and hypertension, while maintaining a robust pipeline of innovative and improved generic candidates. Located in the China Pharmaceutical Port, Hechen is dedicated to delivering high-quality pharmaceutical solutions across therapeutic areas such as neurology, respiratory, and oncology.